Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $306.93, for a total value of $1,012,869.00. Following the completion of the transaction, the director now owns 338,268 shares in the company, valued at $103,824,597.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
ILMN opened at $319.03 on Friday. The firm has a market cap of $46.87 billion, a P/E ratio of 55.77, a PEG ratio of 2.39 and a beta of 1.17. Illumina, Inc. has a 1 year low of $226.62 and a 1 year high of $372.61. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 0.23.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). The firm had revenue of $867.00 million for the quarter, compared to analyst estimates of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. Illumina’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.44 EPS. As a group, analysts predict that Illumina, Inc. will post 6.53 earnings per share for the current year.
A number of equities analysts recently issued reports on ILMN shares. Morgan Stanley decreased their target price on Illumina from $320.00 to $288.00 and set an “equal weight” rating on the stock in a report on Monday, January 7th. BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a report on Wednesday, February 13th. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a report on Monday, December 31st. Deutsche Bank cut Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price on the stock. in a report on Friday, January 25th. Finally, Bank of America restated a “buy” rating and issued a $355.00 target price on shares of Illumina in a report on Wednesday, January 30th. Three research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $346.97.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Story: Balanced Fund
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.